Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 26, 2015 09:00 ET | Source: Zogenix

Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study

SAN DIEGO, March 26, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
March 10, 2015 16:05 ET | Source: Zogenix

Zogenix Reports Fourth Quarter and Full Year 2014 Financial Results

Clinical and Regulatory Update Received FDA approval for new formulation of Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, with BeadTek™ On track to begin...
March 10, 2015 16:05 ET | Source: Zogenix

Zogenix Announces Agreement of Sale of Zohydro(R) ER Business to Pernix for $100 Million at Closing Plus Potential Milestones of $283.5 Million

Enables planned implementation of new strategic focus to developing a late-stage, high-value CNS pipeline Conference Call and Webcast on Tuesday, March 10, at 4:30 p.m. ET Agreement...
March 02, 2015 16:05 ET | Source: Zogenix

Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2014 Financial Results

SAN DIEGO, March 2, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
February 10, 2015 16:01 ET | Source: Zogenix

Zogenix Appoints Industry Veteran Renee Tannenbaum to Its Board of Directors

SAN DIEGO, Feb. 10, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
February 05, 2015 09:00 ET | Source: Zogenix

Zogenix to Participate in Leerink Global Healthcare Conference

SAN DIEGO, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
January 30, 2015 19:05 ET | Source: Zogenix

Zogenix Receives FDA Approval of New Formulation of Zohydro(R) ER

SAN DIEGO, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
January 12, 2015 07:30 ET | Source: Zogenix

Zogenix Provides Business Update

SAN DIEGO, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central...
December 03, 2014 16:30 ET | Source: Zogenix

Zogenix to Participate in Oppenheimer 25th Annual Healthcare Conference

SAN DIEGO, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central...
December 01, 2014 08:30 ET | Source: Zogenix

Results of Long-Term, Open-Label Study Published in the Journal of Pain Research Demonstrate the Safety, Tolerability and Effectiveness of Zohydro(R) ER

SAN DIEGO, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system...

Next Page keyboard_arrow_right